New prostaglandin derivative for glaucoma treatment.
A hydrogen sulphide-releasing derivative of latanoprost acid (ACS 67) was synthesized and tested in vivo to evaluate its activity on reduction of intraocular pressure and tolerability. Glutathione (GSH) and cGMP content were also measured in the aqueous humour. The increased reduction of intraocular pressure, with a marked increase of GSH and cGMP and the related potential neuroprotective properties, make this compound interesting for the treatment of glaucoma. This is the first time that an application of a hydrogen sulphide-releasing molecule is reported for the treatment of ocular diseases.
Perrino
Elena
E
Istituto di Chimica Farmaceutica e Tossicologica 'Pietro Pratesi', University of Milan, Via Mangiagalli 25, 20133 Milan, Italy.
Uliva
Caterina
C
Lanzi
Cecilia
C
Soldato
Piero Del
PD
Masini
Emanuela
E
Sparatore
Anna
A
D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D015195:Drug Design; D005128:Eye Diseases / Q000188:drug therapy*; D005901:Glaucoma / Q000628:therapy*; D005978:Glutathione / Q000737:chemistry; D006862:Hydrogen Sulfide / Q000737:chemistry; D007429:Intraocular Pressure; D000077338:Latanoprost; D008956:Models, Chemical; D018696:Neuroprotective Agents / Q000494:pharmacology; D011453:Prostaglandins / Q000627:therapeutic use*; D011461:Prostaglandins F, Synthetic / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011817:Rabbits; D013997:Time Factors
D018696:Neuroprotective Agents; D011453:Prostaglandins; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D005978:Glutathione; D006862:Hydrogen Sulfide